Asset
VESTRONIDASE ALFA
Ultragenyx Pharmaceutical Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02230566 | phase3 | completed | 2014-12-01 | 2016-05-01 | Ultragenyx Pharmaceutical Inc | A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) |
| NCT02432144 | phase3 | completed | 2015-11-10 | 2019-01-14 | Ultragenyx Pharmaceutical Inc | A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) |
| NCT01856218 | phase1_2 | completed | 2013-11-01 | 2016-07-01 | Ultragenyx Pharmaceutical Inc | An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) |
| NCT02418455 | phase2 | completed | 2015-07-21 | 2019-03-26 | Ultragenyx Pharmaceutical Inc | Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age |
FDA applications (0)
This company has no applications containing this asset.